The stock of ChromaDex Corporation (NASDAQ:CDXC) last traded at $1.84, unchanged from the previous session.
Data from the available sources indicates that ChromaDex Corporation (NASDAQ:CDXC) is covered by 6 analysts. The consensus rating among analysts is ‘Overweight’. CDXC stock price is now 26.30% away from the 50-day moving average and -4.25% away from the 200-day moving average. The market capitalization of the company currently stands at $137.01M.
In total, 2 analysts have assigned it a hold rating, and 4 have given it a buy rating.
On August 11, 2022, B. Riley Securities Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $6 to quote $2.40, while ‘ROTH Capital’ rates the stock as ‘Buy’.
In other news, Fried Robert N, Cheif Executive Officer bought 80,000 shares of the company’s stock on Sep 30. The stock was bought for $100,000 at an average price of $1.25. Upon completion of the transaction, the Cheif Executive Officer now directly owns 972,314 shares in the company, valued at $1.79 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 30, 10% Owner Chau Hoi Shuen Solina Holly bought 960,000 shares of the business’s stock. A total of $1,200,000 was incurred on buying the stock at an average price of $1.25. This leaves the insider owning 7,885,641 shares of the company worth $14.51 million. A total of 12.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CDXC stock. A new stake in ChromaDex Corporation shares was purchased by MILLENNIUM MANAGEMENT LLC during the first quarter worth $1,405,000. ERGOTELES LLC invested $424,000 in shares of CDXC during the first quarter. In the first quarter, QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in ChromaDex Corporation valued at approximately $82,000. HRT FINANCIAL LP acquired a new stake in CDXC for approximately $70,000. GABELLI FUNDS LLC purchased a new stake in CDXC valued at around $52,000 in the second quarter. In total, there are 99 active investors with 19.60% ownership of the company’s stock.
With an opening price of $1.8100 on Friday morning, ChromaDex Corporation (NASDAQ: CDXC) set off the trading day. During the past 12 months, ChromaDex Corporation has had a low of $1.15 and a high of $6.19. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.30, and a quick ratio of 1.30. The fifty day moving average price for CDXC is $1.4652 and a two-hundred day moving average price translates $1.9175 for the stock.
The latest earnings results from ChromaDex Corporation (NASDAQ: CDXC) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.09, missing analysts’ expectations of -$0.08 by -0.01. This compares to -$0.13 EPS in the same period last year. The net profit margin was -29.70% and return on equity was -82.30% for CDXC. The company reported revenue of $17.06 million for the quarter, compared to $17.31 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.42 percent. For the current quarter, analysts expect CDXC to generate $18.69M in revenue.
ChromaDex Corporation(CDXC) Company Profile
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.